## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.4% in lower entry zone (4.0-10.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (7.6%) confirms momentum alignment. Strong momentum (+11.5% 5-day acceleration). Outperforming sector by 9.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($113.87)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC**
- Source: MarketBeat | 20251208T111009 | Bullish | Relevance: 99%
-  Kennedy Capital Management LLC increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 7.1% during the second quarter, now owning 241,188 shares valued at $1.85 million. Several other institutional investors also increased their holdings, bringing total institutional ownership to 47.91%. Analysts currently rate Abivax with a "Moderate Buy" and an average target price of $123.00, while the company's lead drug candidate, obefazimod, is in Phase 3 trials for ulcerative colitis.

**2. Abivax Stock: What Lies Ahead?**
- Source: StocksToTrade | 20251210T020903 | Bullish | Relevance: 98%
-  Abivax SA stock is trending up due to positive sentiment from promising Phase 3 trial results for obefazimod in ulcerative colitis and upcoming Phase 2b data in Crohn’s disease. Analysts have issued a "Buy" rating with a target price of $140, highlighting the drug's unique mechanism and broad immune effects. The company reported strong financial results, including $812M in revenue and $468M in Free Cash Flow, positioning it well for future growth driven by these significant clinical milestones.

**3. Abivax (NASDAQ:ABVX) Reaches New 52-Week High - Should You Buy?**
- Source: MarketBeat | 20251210T160903 | Bullish | Relevance: 98%
- Abivax (NASDAQ:ABVX) hit a new 52-week high of $137.00, trading strongly at $134.699 with a $10.62 billion market cap. Wall Street analysts maintain a "Moderate Buy" rating with an average $123.00 price target, with Guggenheim raising its objective to $150. The biotech company is developing obefazimod for ulcerative colitis and has seen increased institutional holdings despite negative EPS forecasts.

**4. Is Obefazimod’s Phase 3 UC Success Reshaping The Investment Case For ABIVAX (ENXTPA:ABVX)?**
- Source: Simply Wall Street | 20251210T030903 | Somewhat-Bullish | Relevance: 98%
-  Abivax's lead candidate, obefazimod, has shown statistically significant success in Phase 3 trials for ulcerative colitis, leading the company to plan a U.S. regulatory submission by late 2026. While these results strengthen the short-term outlook and have driven a significant share price increase, the company remains clinical-stage and loss-making, with its investment narrative heavily reliant on regulatory approval and future financing. Investors must weigh the potential for a commercially viable drug against the risks of cash burn, dilution, and negative equity.

**5. Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX)**
- Source: MarketBeat | 20251209T160928 | Bullish | Relevance: 98%
-  Abivax (NASDAQ:ABVX) experienced unusually large options trading volume on Tuesday, with traders purchasing 3,575 call options, an 82% increase over the daily average. This activity comes as analysts have raised price targets and ratings, with a consensus "Moderate Buy" rating and an average target of $123. The clinical-stage biotech is advancing its lead drug obefazimod in Phase 3 trials for ulcerative colitis, and its shares traded up about 5.9% to $121.85 amid the increased interest.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +11.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.1B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -5.1% to 6.4% (+11.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 7.6% confirms short-term momentum alignment. AM_20 at 9.1% shows strong absolute momentum above own 20MA. Outperforming sector by 9.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.7x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.43% (CS: 86) | Strong |
| RSI_14 | 66.0 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 1.091x | Above |
| vs SMA50 | 1.232x | Above |
| vs SMA200 | 2.637x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $127.53
- **Stop Loss:** $113.87 (10.7% risk)
- **Target:** $148.02 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $4,591.08
- **Portfolio %:** 4.59%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*